Depletion of Human Regulatory T Cells

Methods in Molecular Biology

Volumn 707, Issue , 2011, Pages 219-231

  Hobeika, Amy C ^a   Morse, Michael A ^a   Osada, Takuya ^a   Peplinski, Sharon ^a   Lyerly, H Kim ^b   Clay, Timothy M ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b DUKE CANCER INSTITUTE   (United States)

Author keywords

Antigen specific T cells; Cancer; Denileukin diftitox; Regulatory T cells; Tumor antigen

Indexed keywords

DENILEUKIN DIFTITOX; DIPHTHERIA TOXIN; HYBRID PROTEIN; INTERLEUKIN 2; TUMOR ANTIGEN;

ARTICLE; DRUG EFFECT; HUMAN; IMMUNOLOGY; LYMPHOCYTE DEPLETION; METHODOLOGY; NEOPLASM; REGULATORY T LYMPHOCYTE;

ANTIGENS, NEOPLASM; DIPHTHERIA TOXIN; HUMANS; INTERLEUKIN-2; LYMPHOCYTE DEPLETION; NEOPLASMS; RECOMBINANT FUSION PROTEINS; T-LYMPHOCYTES, REGULATORY;

EID: 79955693786     PISSN: 10643745     EISSN: 19406029     Source Type: Book Series    
DOI: 10.1007/978-1-61737-979-6_14     Document Type: Chapter

References (30)

1. Shevach, E. M., DiPaolo, R. A., Andersson, J., Zhao, D. M., Stephens, G. L., and Thornton, A. M. (2006) The lifestyle of naturally occurring CD4+ CD25+ Foxp3+ regulatory T cells. Immunol. Rev. 212, 60–73.
2. Ahmad, M., Rees, R. C., and Ali, S. A. (2004) Escape from immunotherapy: possible mechanisms that influence tumor regression/pro-gression. Cancer Immunol. Immunother. 53, 844–854.
3. Terabe, M., and Berzofsky, J. A. (2004) Immunoregulatory T cells in tumor immunity. Curr. Opin. Immunol. 16, 157–162.
4. Onizuka, S., Tawara, I., Shimizu, J., Sakaguchi, S., Fujita, T., and Nakayama, E. (1999) Tumor rejection by in vivo administration of anti-CD25 (interleukin-2 receptor a) monoclonal antibody. Cancer Res. 59, 3128–3133.
5. Sakaguchi, S., Sakaguchi, N., Asano, M., Itoh, M., and Toda, M. (1995) Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor a-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J. Immunol. 155, 1151–1164.
6. Sakaguchi, S., Sakaguchi, N., Shimizu, J., Yamazaki, S., Sakihama, T., Itoh, M., et al. (2001) Immunologic tolerance maintained by CD25+CD4+ regulatory T cells: their common role in controlling autoimmunity, tumor immunity, and transplantation tolerance. Immunol. Rev. 182, 18–32.
7. Shimizu, J., Yamazaki, S., and Sakaguchi, S. (1999) Induction of tumor immunity by removing CD25+CD4+ T cells: a common basis between tumor immunity and autoimmunity. J. Immunol. 163, 5211–5218.
8. Asseman, C., Mauze, S., Leach, M. W., Coffman, R. L., and Powrie, F. (1999) An essential role for interleukin 10 in the function of regulatory T cells that inhibit intestinal inflammation. J. Exp. Med. 190, 995–1004.
9. Lombardi, G., Sidhu, S., Batchelor, R., and Lechler, R. (1994) Anergic T cells as suppressor cells in vitro. Science 264, 1587–1589.
10. Seddon, B., and Mason, D. (1999) Regulatory T cells in the control of autoimmunity: the essential role of transforming growth factor beta and interleukin 4 in the prevention of autoimmune thyroiditis in rats by peripheral CD4(+)CD45RC-cells and CD4(+)CD8(−) thymocytes. J. Exp. Med. 189, 279–288.
11. Thornton, A. M., and Shevach, E. M. (1998) CD4+CD25+ immunoregulatory T cells suppress polyclonal T cell activation in vitro by inhibiting interleukin 2 production. J. Exp. Med. 188, 287–296.
12. Morse, M. A., Clay, T. M., Hobeika, A. C, Osada, T., Khan, S., Chui, S., et al. (2005) Phase I study of immunization with dendritic cells modified with fowlpox encoding carcino-embryonic antigen and costimulatory molecules. Clin. Cancer Res. 15, 3017–3024.
13. Curiel, T. J., Coukos, G., Zou, L., Alvarez, X., Cheng, P., Mottram, P., et al. (2004) Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat. Med. 10, 942–949.
14. Liyanage, U. K., Moore, T. T., Joo, H. G., Tanaka Y., Herrmann, V., Doherty, G., et al. (2002) Prevalence of regulatory T cells is increased in peripheral blood and tumor microenvironment of patients with pancreas or breast adenocarcinoma. J. Immunol. 169, 2756–2761.
15. Small, E. J., Schellhammer, P. F., Higano, C. S., Redfern, C. H., Nemunaitis, J. J., Valone, F. H., et al. (2006) Placebo-controlled phase III trial of immunologic therapy with sipuleu-cel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer. J. Clin. Oncol. 24, 3089–3094.
16. Wolf, A. M., Wolf, D., Steurer, M., Gastl, G., Gunsilius, E., and Grubeck-Loebenstein, B. (2003) Increase of regulatory T cells in the peripheral blood of cancer patients. Clin. Cancer Res. 9, 606–612.
17. Viguier, M., Lemaitre, F., Verola, O., Cho, M. S., Gorochov, G., Dubertret, L., et al. (2004) Foxp3 expressing CD4+CD25(high) regulatory T cells are overrepresented in human metastatic melanoma lymph nodes and inhibit the function of infiltrating T cells. J. Immunol. 173, 1444–1453.
18. Woo, E. Y., Yeh, H., Chu, C. S., Schlienger, K., Carroll, R. G, Riley, J. L., et al. (2002) Cutting edge: regulatory T cells from lung cancer patients directly inhibit autologous T cell proliferation. J. Immunol. 168, 4272–4276.
19. Hussain, S. F., and Paterson, Y. (2004) CD4+CD25+ regulatory T cells that secrete TGFbeta and IL-10 are preferentially induced by a vaccine vector. J. Immunother. 27, 339–346.
20. Casares, N., Arribillaga, L., Sarobe, P., Dotor, J., Lopez-Diaz de Cerio, A., Melero, I., et al. (2003) CD4+/CD25+ regulatory cells inhibit activation of tumor-primed CD4+ T cells with IFN-gamma-dependent antiangiogenic activity, as well as long-lasting tumor immunity elicited by peptide vaccination. J. Immunol. 171, 5931–5939.
21. Nagai, H., Horikawa, T., Hara, I., Fukunaga, A., Oniki, S., Oka, M., et al. (2004) In vivo elimination of CD25+ regulatory T cells leads to tumor rejection of B16F10 melanoma, when combined with interleukin-12 gene transfer. Exp. Dermatol. 13, 613–620.
22. Turk, M. J., Guevara-Patino, J. A., Rizzuto, G. A., Engelhorn, M. E., and Houghton, A. N. (2004) Concomitant tumor immunity to a poorly immunogenic melanoma is prevented by regulatory T cells. J. Exp. Med. 200, 771–782.
23. + regulatory T cells [Abstract]. J. Clin. Oncol. 2004 ASCO Annual Meeting Proceedings. 22, 2506.
24. Morse, M. A., Hobeika, A. C., Osada, T., Serra, D., Niedzwiecki, D., Lyerly, H. K., et al. (2008) Depletion of human regulatory T cells specifically enhances antigen-specific immune responses to cancer vaccines. Blood 112, 610–618.
25. Almeida, A. R., Legrand, N., Papiernik, M., and Freitas, A. A. (2002) Homeostasis of peripheral CD4+ T cells: IL-2a and IL-2 shape a population of regulatory cells that controls CD4+ T cell numbers. J. Immunol. 169, 4850–4860.
26. Taniguchi, T., and Minami, Y. (1993) The IL-2/IL-2 receptor system: a current overview. Cell 73, 5–8.
27. 389 IL2 diphtheria fusion toxin produces clinical responses in tumor stage cutaneous T cell lymphoma. Am. J. Hematol. 58, 87–90.
28. Olsen, E., Duvic, M., and Frankel, A. (2001) Pivotal phase III trial of two dose levels of denileukin diftitox for the treatment of cutaneous T-cell lymphoma. J. Clin. Oncol. 19, 376–388.
29. Waters, C. A., Schimke, P. A., Snider, C. E., Itoh, K., Smith, K. A., Nichols, J. C., et al. (1990) Interleukin 2 receptor-targeted cytotoxicity. Receptor binding requirements for entry of a diphtheria toxin-related interleukin 2 fusion protein into cells. Eur. J. Immunol. 20, 785–791.
30. Disis, M. L., dela Rosa, C., Goodell, V., Kuan, L. Y., Chang, J. C., Kuus-Reichel, K., et al. (2006) Maximizing the retention of antigen specific lymphocyte function after cr yopreservation. J. Immunol. Methods 308, 13–18.